open access

Vol 7, No 6 (2011)
Review paper
Published online: 2012-02-27
Get Citation

Hypertension and molecular targeted therapy — complication either biomarker of effective therapy?

Magdalena Knetki-Wróblewska
Onkol. Prak. Klin 2011;7(6):279-291.

open access

Vol 7, No 6 (2011)
REVIEW ARTICLES
Published online: 2012-02-27

Abstract

A few molecular-targeted drugs that inhibit neoangiogenesis were implemented last years. Hypertension is a common side effect of treatment with antiangiogenic agents, and may affect up to 80%
of patients. Poorly controlled hypertension is a recognized risk factor for cardiovascular and organ complications and should be diagnosed and treated properly. On the other hand it is observed that
hypertension induced by antiangiogenic therapy is associated with higher probability of clinical benefit in some patients.
It still remains difficult to indicate patients in which the arterial hypertension is likely to occur. No reliable biomarkers which may select this population or clearly correlate with development of hypertension
have been identified. Universal algorithms of diagnosis and treatment of iatrogenic hypertension are not available. Cardiovascular risk factors and other comorbidities should be considered before decision about antiangiogenic therapy. Due to increasing number of drugs with this mechanism of action it is important to create algorithms of diagnosis and treatment. Prospective randomized trials may be crucial to determine
predictive value of arterial hypertension induced by angiogenesis inhibitors.

Abstract

A few molecular-targeted drugs that inhibit neoangiogenesis were implemented last years. Hypertension is a common side effect of treatment with antiangiogenic agents, and may affect up to 80%
of patients. Poorly controlled hypertension is a recognized risk factor for cardiovascular and organ complications and should be diagnosed and treated properly. On the other hand it is observed that
hypertension induced by antiangiogenic therapy is associated with higher probability of clinical benefit in some patients.
It still remains difficult to indicate patients in which the arterial hypertension is likely to occur. No reliable biomarkers which may select this population or clearly correlate with development of hypertension
have been identified. Universal algorithms of diagnosis and treatment of iatrogenic hypertension are not available. Cardiovascular risk factors and other comorbidities should be considered before decision about antiangiogenic therapy. Due to increasing number of drugs with this mechanism of action it is important to create algorithms of diagnosis and treatment. Prospective randomized trials may be crucial to determine
predictive value of arterial hypertension induced by angiogenesis inhibitors.
Get Citation

Keywords

arterial hypertension; antiangiogenic agents; predictive factor

About this article
Title

Hypertension and molecular targeted therapy — complication either biomarker of effective therapy?

Journal

Oncology in Clinical Practice

Issue

Vol 7, No 6 (2011)

Article type

Review paper

Pages

279-291

Published online

2012-02-27

Bibliographic record

Onkol. Prak. Klin 2011;7(6):279-291.

Keywords

arterial hypertension
antiangiogenic agents
predictive factor

Authors

Magdalena Knetki-Wróblewska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl